Bio-Rad Laboratories, Inc.
BIO
$238.68
-$2.34-0.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.54B | 2.57B | 2.58B | 2.56B | 2.61B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.54B | 2.57B | 2.58B | 2.56B | 2.61B |
| Cost of Revenue | 1.18B | 1.19B | 1.18B | 1.18B | 1.21B |
| Gross Profit | 1.36B | 1.38B | 1.40B | 1.38B | 1.39B |
| SG&A Expenses | 793.92M | 810.92M | 814.08M | 814.74M | 826.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26B | 2.29B | 2.27B | 2.22B | 2.28B |
| Operating Income | 279.89M | 274.69M | 311.68M | 338.27M | 327.69M |
| Income Before Tax | -2.75B | -2.34B | -1.01B | -1.73B | -443.83M |
| Income Tax Expenses | -586.06M | -498.26M | -226.48M | -404.09M | -121.47M |
| Earnings from Continuing Operations | -2.16K | -1.84K | -778.68 | -1.33K | -322.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.16B | -1.84B | -778.68M | -1.33B | -322.36M |
| EBIT | 279.89M | 274.69M | 311.68M | 338.27M | 327.69M |
| EBITDA | 432.49M | 426.29M | 461.28M | 486.27M | 475.09M |
| EPS Basic | -76.17 | -65.00 | -27.28 | -47.00 | -10.33 |
| Normalized Basic EPS | 7.15 | 6.93 | 7.75 | 8.42 | 8.09 |
| EPS Diluted | -76.20 | -65.04 | -27.34 | -47.04 | -10.37 |
| Normalized Diluted EPS | 7.14 | 6.93 | 7.74 | 8.41 | 8.07 |
| Average Basic Shares Outstanding | 112.28M | 112.86M | 113.65M | 114.81M | 115.77M |
| Average Diluted Shares Outstanding | 112.33M | 112.91M | 113.73M | 114.97M | 115.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |